Stoked Bio
AI-assisted MOSAIC platform for small-molecule drugs against resistant infections, cancers, Crohn's
Website: https://stokedbio.com
Cover Block
PUBLIC
| Name | Stoked Bio |
| Tagline | AI-assisted MOSAIC platform for small-molecule drugs against resistant infections, cancers, Crohn's |
| Headquarters | Canada |
| Stage | Seed |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding Label | Seed (total disclosed ~$2,500,000) |
Links
PUBLIC
- Website: https://stokedbio.com
- LinkedIn: https://www.linkedin.com/company/stoked-bio
Executive Summary
PUBLIC Stoked Bio is a preclinical biotechnology startup using a proprietary, biology-first AI platform to discover novel small-molecule drugs for conditions with high unmet need, including antimicrobial resistance, glioblastoma, and Crohn's disease [Perplexity Sonar Pro, Unknown]. The company's immediate investor appeal lies in its exclusive control over a promising clinical asset, Enterololin, and its academic roots in a lab with a published track record of antibiotic discovery [GlobeNewswire, Feb 2026] [MIT News, 2025].
The venture originated from the Stokes Lab at McMaster University, translating academic research into a commercial drug discovery engine called MOSAIC [Creative Destruction Lab, Unknown]. This platform is designed to identify and optimize patentable drug candidates, advancing them to a stage ready for partnership with larger pharmaceutical companies [stokedbio.com/what-we-do/, Unknown]. The founding team combines deep scientific expertise from McMaster with commercial leadership, though specific prior venture experience is not detailed in public sources.
Capitalization is light, with a seed round of undisclosed size recently closed, supported by participation in the Creative Destruction Lab accelerator [BioSpace, Unknown] [Creative Destruction Lab, Unknown]. The business model is asset-centric, aiming to license or out-license programs rather than build commercial infrastructure. Over the coming 12-18 months, the critical milestones to watch are preclinical data readouts for Enterololin, the progression of other pipeline candidates, and the securing of a first pharmaceutical development partnership.
Data Accuracy: YELLOW -- Core company claims are self-published; key facts like funding size and team backgrounds lack independent corroboration.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Seed |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding | Seed (total disclosed ~$2,500,000) |
Company Overview
PUBLIC
Stoked Bio is a Canadian biotechnology company that emerged from academic research at McMaster University, specifically the Stokes Lab. The company's formation is a direct translation of that lab's work into a commercial venture, a path common for early-stage biotechs. Its public identity is anchored by a recent, significant milestone: securing an exclusive global license for a novel antibiotic program from its academic birthplace.
The company's headquarters are in Canada, though a specific city is not detailed in public filings. The founding team includes Jonathan Stokes, whose lab originated the core technology, alongside Jeff Skinner, who serves as CEO, and Chris Sinclair. The company has participated in the Creative Destruction Lab accelerator program, a common early validation step for science-based Canadian startups [Creative Destruction Lab].
A key chronological milestone occurred on February 18, 2026, when Stoked Bio announced it had secured an exclusive global license from McMaster University for Enterololin, a narrow-spectrum antibiotic initially researched for Crohn's disease [GlobeNewswire, Feb 2026]. This license represents the first publicly disclosed asset transfer from the university to the company, formalizing its pipeline. The company also announced the closing of a seed financing round, though the amount and participants were not disclosed [BioSpace].
Data Accuracy: YELLOW -- Company website and press releases provide core details; founding year and specific HQ location are not publicly available.
Product and Technology
MIXED Stoked Bio's core asset is the MOSAIC platform, a biology-driven AI system designed to discover and optimize small-molecule drug candidates from initial screening to Investigational New Drug (IND) readiness [stokedbio.com/what-we-do/]. The platform's stated purpose is to generate patentable assets for partnering with pharmaceutical companies, focusing on areas of high unmet need like antimicrobial resistance and cancers resistant to current treatments [Creative Destruction Lab].
The technology is described as a full-stack approach, integrating AI for molecular property prediction and design across any therapeutic area [stokedbio.com/what-we-do/]. Its first tangible output is the Enterololin program, a narrow-spectrum antibiotic for Crohn's disease for which Stoked Bio secured an exclusive global license from McMaster University in February 2026 [GlobeNewswire, Feb 2026]. The company claims to have four initial novel programs targeting resistant infections and cancer, though specific molecular targets or stages are not detailed [Perplexity Sonar Pro]. The platform's development originated from the Stokes Lab at McMaster University, suggesting a foundation in academic research and proprietary biological datasets.
Data Accuracy: YELLOW -- Core platform claims are from the company website; the license agreement is confirmed by a press release. Specific technical capabilities and program details lack independent verification.
Market Research
PUBLIC The urgency to develop new small-molecule therapeutics is driven by a convergence of rising antimicrobial resistance, intractable cancers, and the high failure rates of traditional drug discovery pipelines, a pressure point that creates a receptive market for platform-based approaches.
Quantifying the total addressable market (TAM) for Stoked Bio's platform is challenging due to its early-stage, multi-indication focus. The company's public materials do not cite specific market sizing figures. However, analogous market reports provide context for the therapeutic areas it targets. The global market for novel antibiotics to combat antimicrobial resistance (AMR) is projected to reach $12.1 billion by 2030, according to a report cited by the World Health Organization [WHO]. For glioblastoma, the market for therapeutics is estimated at $3.2 billion in 2024, with growth driven by high unmet need [Grand View Research]. The inflammatory bowel disease (IBD) drug market, which includes Crohn's disease, is a larger adjacent space, valued at approximately $25 billion globally [GlobalData]. These figures represent the potential revenue for approved drugs, not the value of discovery platforms, but they illustrate the economic weight of the problems Stoked Bio is addressing.
Key demand drivers extend beyond market size. The primary tailwind is the escalating global health threat of antimicrobial resistance, which the WHO classifies as one of the top ten global public health threats [WHO]. This has spurred governmental and non-profit funding initiatives, such as the CARB-X accelerator and the AMR Action Fund, which aim to de-risk early-stage antibiotic development. A second driver is the persistent high failure rate in oncology drug development, particularly for solid tumors like glioblastoma, creating demand for novel discovery methods that can improve candidate quality. The company's exclusive license for Enterololin, a narrow-spectrum antibiotic for Crohn's disease, also positions it within a shift towards microbiome-targeted therapies, a growing sub-sector within gastroenterology [Nature Reviews Gastroenterology & Hepatology].
Regulatory and macro forces present a mixed picture. On one hand, regulatory pathways for drugs targeting unmet medical needs, like Qualified Infectious Disease Product (QIDP) designation in the U.S., can offer incentives such as priority review and extended market exclusivity. On the other hand, the biotech funding environment remains constrained, making capital efficiency and clear de-risking milestones critical for early-stage companies. The long development timelines and high capital requirements for bringing a drug to IND (Investigational New Drug application) readiness mean market entry is measured in years, not quarters.
| Metric | Value |
|---|---|
| Antimicrobial Resistance (AMR) Drug Market | 12.1 $B (2030) |
| Glioblastoma Therapeutics Market | 3.2 $B (2024) |
| Inflammatory Bowel Disease (IBD) Drug Market | 25 $B |
The chart illustrates the substantial revenue pools in Stoked Bio's target and adjacent markets, though these figures represent the end-market for approved drugs, not the serviceable market for a preclinical discovery platform. The platform's ultimate value will be a fraction of these totals, contingent on successful asset out-licensing.
Data Accuracy: YELLOW -- Market sizing figures are drawn from analogous third-party industry reports, not company-provided projections. Therapeutic area focus is confirmed by company sources.
Competitive Landscape
MIXED
Stoked Bio enters a competitive field by focusing on a biology-first AI platform to generate small-molecule drug candidates for specific, high-burden conditions.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Stoked Bio | AI-assisted (MOSAIC) platform for small-molecule discovery against resistant infections, cancers, Crohn's. | Seed stage; undisclosed round. | Exclusive global license for Enterololin antibiotic from McMaster University; academic spinout with biology-driven AI approach. | [GlobeNewswire, Feb 2026]; [Creative Destruction Lab] |
| Absci | Generative AI for de novo antibody and protein drug discovery. | Public (NASDAQ: ABSI); $200M+ in funding. | Integrated wet-lab platform for zero-shot generation and validation of novel biologics. | [Absci corporate filings, 2025] |
| Recursion | AI-powered drug discovery platform mapping cellular biology for multiple therapeutic areas. | Public (NASDAQ: RXRX); $1B+ in funding. | Massive proprietary dataset of phenomics images and automated wet-lab validation at scale. | [Recursion investor presentations, 2025] |
| Exscientia | AI-driven small-molecule design and clinical development. | Public (NASDAQ: EXAI); $500M+ in funding. | Multiple AI-designed molecules in clinical trials; established partnerships with major pharma. | [Exscientia corporate website, 2025] |
This competitive map breaks into three primary segments. The first is the platform-focused public AI biotechs like Recursion and Exscientia, which have raised and spent significant capital to build large-scale discovery engines and advance assets into the clinic [Recursion investor presentations, 2025] [Exscientia corporate website, 2025]. The second segment includes companies like Absci, which focus on a specific modality, in its case generative AI for novel biologics [Absci corporate filings, 2025]. Stoked Bio currently occupies a third, more focused niche: early-stage, academically rooted platforms targeting a defined set of diseases with a biology-first AI methodology.
Stoked Bio's defensible edge today rests on its exclusive access to foundational intellectual property and the academic pedigree of its platform. The exclusive global license for Enterololin, a narrow-spectrum antibiotic with potential in Crohn's disease, provides a tangible, patent-protected asset that de-risks at least one program's initial development path [GlobeNewswire, Feb 2026]. Furthermore, the MOSAIC platform originated within the Stokes Lab at McMaster University, suggesting a deep integration of biological expertise with computational tools, a contrast to more purely computational approaches [Synapse Consortium]. This edge is durable if the company can continue to secure and advance high-quality academic IP, but it is perishable if it cannot translate that academic foundation into a repeatable, scalable discovery process that outpaces well-funded competitors.
The company's most significant exposure is its preclinical stage and lack of disclosed commercial traction or pharma partnerships. Competitors like Exscientia have demonstrated the ability to move AI-designed molecules into clinical trials and secure large partnership deals, validating both their technology and their business development capabilities [Exscientia corporate website, 2025]. Stoked Bio has not yet publicly shown it can execute on those critical, capital-intensive steps. It also lacks the massive, proprietary datasets that underpin the platforms of companies like Recursion, which could limit the predictive power and scope of its AI models over time.
The most plausible 18-month competitive scenario hinges on Stoked Bio's ability to de-risk its lead asset and secure a development partner. A winner scenario would see the company advance Enterololin through key preclinical milestones and announce a licensing or co-development deal with a mid-sized pharma company focused on gastrointestinal diseases. This would validate its platform's ability to generate partnerable assets and provide non-dilutive capital. A loser scenario would involve stagnation, where the company fails to progress its lead program or generate new compelling data, while better-funded platform competitors continue to announce new clinical candidates and partnerships, widening the credibility and resource gap. In this case, Stoked Bio risks being perceived as an interesting academic project rather than a competitive drug discovery engine.
Data Accuracy: YELLOW -- Competitor profiles are based on public corporate materials; Stoked Bio's differentiation is cited from press releases and program descriptions.
Opportunity
PUBLIC
If Stoked Bio's platform can systematically generate novel, patentable drug candidates against intractable diseases, the commercial prize is a portfolio of high-value clinical assets, each representing a potential billion-dollar licensing deal or acquisition by a major pharmaceutical company.
The headline opportunity is to become a recognized, asset-generating biotech platform, not just a single-program company. The most plausible large outcome is that Stoked Bio's MOSAIC platform proves its repeatability by advancing multiple programs from discovery to IND-ready packages, establishing the company as a preferred partner for pharma seeking to outsource early-stage pipeline innovation. The evidence for this reachable outcome, rather than a purely aspirational one, begins with the company's academic roots and exclusive license. Originating from the Stokes Lab at McMaster University provides a foundation in published biology and a direct channel to university intellectual property, as demonstrated by the February 2026 exclusive global license for Enterololin [GlobeNewswire, Feb 2026]. This move from platform concept to a concrete, in-licensed asset is a critical first step toward validating the business model of identifying and developing external candidates.
Growth for a preclinical biotech is path-dependent, hinging on technical validation, capital, and partnership decisions. The following scenarios outline concrete paths to scaling the platform's output and value.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Platform Partnership | A major pharma enters a multi-program discovery alliance, providing non-dilutive funding and downstream rights. | The company publishes robust preclinical data for a second, wholly-owned program generated by MOSAIC. | The company's stated focus is advancing candidates to IND readiness for partnering [stokedbio.com]. The Creative Destruction Lab affiliation provides a network to potential corporate partners [Creative Destruction Lab]. |
| Portfolio Build & Exit | The company advances 2-3 assets through Phase I proof-of-concept, becoming an attractive acquisition target for a mid-cap biotech. | Successful completion of a Series A round to fund initial clinical trials. | The initial wedge targets high-need areas (antimicrobial resistance, glioblastoma) where clinical success commands significant premiums, and the academic spinout structure is a common precursor to trade sales. |
Compounding in drug discovery often manifests as a data and validation flywheel. Early success with one program, such as Enterololin, generates proprietary biological data and refines the AI models within the MOSAIC platform. This improved platform capability could then increase the speed or success rate of identifying and optimizing subsequent candidates, creating a virtuous cycle where each program de-risks the next. While still early, the company's claim of "continuously improving" its AI models suggests an intent to build this type of capability moat [stokedbio.com].
The size of a win is anchored by comparable transactions in preclinical and early-stage biotech. For a platform company with a partnered asset, valuations can range from the high tens to hundreds of millions of dollars based on upfront payments and milestone structures. A more direct comparable might be the acquisition of a similar AI-driven drug discovery startup by a larger biopharma, which often occurs in the $100 million to $500 million range, depending on the stage and promise of the pipeline. If the "Platform Partnership" scenario plays out, securing a multi-program alliance with upfront funding and significant downstream economics, Stoked Bio could establish a valuation foundation that supports a subsequent high-value exit (scenario, not a forecast).
Data Accuracy: YELLOW -- The core platform claim and license are publicly cited, but growth scenarios are extrapolated from the company's stated model without public validation of partnership talks or pipeline progress beyond the first license.
Sources
PUBLIC
[Perplexity Sonar Pro] Stoked Bio company overview | https://www.perplexity.ai/
[GlobeNewswire, Feb 2026] Stoked Bio Secures Exclusive Global License to Develop a Promising New Therapy for Crohn’s Disease | https://www.globenewswire.com/news-release/2026/02/18/3240347/0/en/stoked-bio-secures-exclusive-global-license-to-develop-a-promising-new-therapy-for-crohn-s-disease.html
[MIT News, 2025] AI maps how a new antibiotic targets gut bacteria | https://news.mit.edu/2025/ai-maps-how-new-antibiotic-targets-gut-bacteria-1003
[Creative Destruction Lab] Stoked Bio company profile | https://creativedestructionlab.com/companies/stoked-bio/
[stokedbio.com/what-we-do/] Stoked Bio What We Do page | https://stokedbio.com/what-we-do/
[BioSpace] Stoked Bio Announces the Closing of Seed Financing Round | https://www.biospace.com/press-releases/stoked-bio-announces-the-closing-of-seed-financing-round
[Synapse Consortium] How Stoked Bio is Using AI to Fight Deadly Diseases | https://synapseconsortium.com/how-stoked-bio-is-using-ai-to-fight-deadly-diseases/
[WHO] World Health Organization on Antimicrobial Resistance | https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
[Grand View Research] Glioblastoma Multiforme Treatment Market Size Report, 2024-2030 | https://www.grandviewresearch.com/industry-analysis/glioblastoma-multiforme-treatment-market
[GlobalData] Inflammatory Bowel Disease (IBD) Market Size and Trend Report | https://www.globaldata.com/store/report/inflammatory-bowel-disease-market-analysis/
[Nature Reviews Gastroenterology & Hepatology] Microbiome-targeted therapies in gastroenterology | https://www.nature.com/articles/s41575-023-00846-4
[Absci corporate filings, 2025] Absci Corporation Investor Relations | https://investors.absci.com/
[Recursion investor presentations, 2025] Recursion Investor Presentations | https://ir.recursion.com/
[Exscientia corporate website, 2025] Exscientia: AI-driven Drug Discovery | https://www.exscientia.ai/
Articles about Stoked Bio
- Stoked Bio Lands an Exclusive License for a Narrow-Spectrum Crohn's Antibiotic — The McMaster University spinout is using its AI-assisted MOSAIC platform to advance a new class of targeted therapeutics from lab to IND.